Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001411685-25-000019
Filing Date
2025-02-13
Accepted
2025-02-13 17:25:15
Documents
58
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q vtgn-20241231.htm   iXBRL 10-Q 1269558
2 EX-31.1 vtgn-20241231xexx311.htm EX-31.1 10134
3 EX-31.2 vtgn-20241231xexx312.htm EX-31.2 10060
4 EX-32 vtgn-20241231xexx32.htm EX-32 5234
  Complete submission text file 0001411685-25-000019.txt   5071207

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtgn-20241231.xsd EX-101.SCH 34957
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vtgn-20241231_cal.xml EX-101.CAL 39937
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vtgn-20241231_def.xml EX-101.DEF 146916
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtgn-20241231_lab.xml EX-101.LAB 499731
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtgn-20241231_pre.xml EX-101.PRE 327057
60 EXTRACTED XBRL INSTANCE DOCUMENT vtgn-20241231_htm.xml XML 444565
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

EIN.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-37761 | Film No.: 25621761
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)